CDKN2C抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Raji cells, Primary antibody: P01195(CDKN2C Antibody) at dilution 1/325, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01195(CDKN2C Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P01195(CDKN2C Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The CDKN2C gene encodes p18INK4C, a member of the INK4 family of cyclin-dependent kinase (CDK) inhibitors that regulate cell cycle progression by binding to CDK4/6. blocking their interaction with cyclin D and preventing G1/S transition. As a tumor suppressor, p18INK4C plays a critical role in maintaining cell cycle control, and its dysregulation is implicated in various cancers. CDKN2C inactivation—through deletions, mutations, or epigenetic silencing—has been observed in malignancies such as multiple myeloma, pituitary tumors, and neuroendocrine cancers, contributing to uncontrolled proliferation.

CDKN2C antibodies are essential tools for studying p18INK4C expression and function in both research and diagnostic contexts. These antibodies enable detection of protein levels via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in the identification of p18INK4C loss or aberrant expression in tumor samples. In research, they help elucidate mechanisms of cell cycle deregulation and therapeutic resistance, particularly in cancers with CDKN2C defects. Clinically, p18INK4C expression patterns may serve as prognostic markers or inform targeted therapy strategies, such as CDK4/6 inhibitor treatments. However, antibody specificity and validation remain crucial to ensure accurate interpretation of p18INK4C’s role in disease pathogenesis and treatment response.